An example of a specific clinical application of plasma ctDNA is the phase IV EGFR tyrosine kinase inhibitor Gefitinib ‘Follow Up Measure’ trial that facilitated the approval of plasma ctDNA testing for EGFR in NSCLC patients (6). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.